Report Scope
This report is an analytical business tool that comprehensively evaluates the global market for women’s health therapeutics. The format of the study is organized around the following topics -
- Detailed study around women’s diseases, such as endometriosis, postmenopausal osteoporosis, menopause, breast cancer and PCOS.
- Disease incidence and prevalence.
- Regulatory structure of pharmaceutical industry.
- Market characterization, unmet need, market size and segmentation.
- Market drivers and restraints.
- Detailed market projections through 2026.
- Competition and market shares.
- Pricing and reimbursement.
- Marketed and pipeline (R&D) products along with description, regulatory status, and clinical trials.
- Observations and conclusions regarding the future of market for women’s health therapeutics.
- Profiles of market participants and associations.
Report Includes
- 58 data tables and 56 additional tables
- An overview of the global market and technologies for women's health therapeutics
- Estimation of the market size and analyses of global market trends, with data from 2018, 2019, 2020, estimates for 2021 and projections of compound annual growth rates (CAGRs) through 2026
- Detailed study around women’s diseases such as endometriosis, postmenopausal osteoporosis, menopause, breast cancer and polycystic ovary syndrome (PCOS); their historical background, stages, symptoms, risk factors and genetic factors, diagnosis, and treatment, etiology, pathophysiology, epidemiology, and economic burden
- Discussion on aging and women’s health disorders, women & sexual health such as female sexual arousal disorder, female orgasmic disorder, and vaginismus and relation between infertility and cancer
- Coverage of regulatory structure, pricing, and reimbursement scenarios; marketed and pipeline (R&D) products, and clinical trials
- Identification of market drivers, restraints and other forces impacting the global market and evaluation of current market size and forecast
- Market share analysis of the key companies of the industry and coverage of their proprietary technologies, strategic alliances, and other key market strategies
- Comprehensive company profiles of the leading players of the industry, including Roche, Eli Lilly, Pfizer, AstraZeneca, Novartis, Amgen, and Merck
Table of Contents
Chapter 1 Introduction
- Study Goals and Objectives
- What's New in this Update?
- Reasons for Doing This Study
- Scope of Report
- Information Sources
- Methodology
- Geographic Breakdown
- Analyst's Credentials
Chapter 2 Summary and Highlights
Chapter 3 Overview of Technologies and Global Markets
- Disease Overview and Definitions
- Historical Background
- Market Driving Factors and Opportunities
- Aging Female Population
- Government Involvement and Increased Funding
- Increasing Awareness Regarding Women's Disorders and Treatments
- Market Restraints
- Poor Diagnosis
- Availability of Alternate Treatment Options and Lifestyle Changes
- Unavailability of Novel Treatments
- High Treatment Cost of Osteoporosis
- Opportunities
- Rising Female Population in Asia-Pacific
- Increased Demand for Technology Innovation
- Mergers and Acquisitions
Chapter 4 Impact of COVID-19 Pandemic
- Implications on Women's Health and Diagnosis
- Implications on Cancer Treatment
- Impact on Oncology Pharmaceuticals Market
Chapter 5 Pipeline Assessment and Analysis
- Women's Health Therapeutics: Key Clinical Trial Developments
- List of Drugs in Pipeline
- Overview of Osteoporosis Drug Development Pipeline
- Late-stage Pipeline Drugs
Chapter 6 Regulatory Structure
- Overview of Regulations
- U.S.
- Canada
- Europe
- Japan
Chapter 7 Market Breakdown by Women’s Health Disorder
- Introduction
- Menopause-Related Diseases
- Overview
- Symptoms
- Risk Factors
- Epidemiology and Economic Burden
- Diagnosis
- Treatments
- Market Size and Forecast
- Postmenopausal Osteoporosis
- Overview
- Epidemiology and Economic Burden
- Diagnosis
- Treatments
- Market Size and Forecasts
- Endometriosis
- Overview
- Epidemiology and Economic Burden
- Diagnosis
- Treatments
- Market Size and Forecasts
- Polycystic Ovary Syndrome
- Overview
- Etiology
- Reducing PCOS Risk
- Epidemiology and Economic Burden
- Disease Symptoms and Risk Factors
- Diagnosis
- Treatments
- Market Size and Forecasts
- Breast Cancer
- Overview
- Market Size and Forecasts
Chapter 8 Market Breakdown by Region
- Introduction
- North America
- U.S.
- Canada
- Mexico
- Europe
- U.K.
- Germany
- France
- Spain
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Rest of Asia-Pacific
- Rest of the World
- South America
- Middle East and Africa
Chapter 9 Pricing and Reimbursement
- Overview of Pricing and Reimbursement
- U.S.
- Canada
- Europe
- Japan
Chapter 10 Competitive Landscape and Key Developments
- Market Players and Strategies
- Blockbuster Breast Cancer Pharmaceutical Brands
- Patent Analysis
- List of Key Patents
- Key Developments
- Mergers and Acquisitions
- Development of Innovative Products/Novel Product Launch
- Agreements, Collaborations and Partnerships
- Key Products
Chapter 11 Company Profiles
- Abbvie Inc.
- Amgen Inc.
- Asahi Kasei
- Astrazeneca plc
- Bayer AG
- Bristol-Myers Squibb
- Daiichi Sankyo Co. Ltd.
- Eli Lilly and Co.
- Eisai
- F. Hoffmann-La Roche Ltd.
- Gilead Sciences Inc.
- Johnson & Johnson Services Inc.
- Merck & Co. Inc.
- Merck Kgaa
- Novartis AG
- Novo Nordisk
- Pfizer Inc.
- Sanofi
- Takeda Pharmaceutical Co. Ltd.
Chapter 12 Conclusions: Outlook for Women’s Health Therapeutics
- Major Developments to Influence Market
- Therapeutic Developments
- Demographic and Economic Trends
- Income Growth in Emerging Markets
- Future Outlook
Chapter 13 Appendix A: Glossary of Terms
Chapter 14 Appendix B: Industry and Professional Organizations
Chapter 15 Appendix C: Acronyms Used in This Report
- Acronyms Used in This Report
List of Tables
Summary Table A : Global Market for Women’s Health Therapeutics and Technologies, by Disease Area, Through 2026
Summary Table B : Global Market for Women’s Health Therapeutics, by Region, Through 2026
Table 1 : Life Expectancy at Birth, Both Sexes Combined, by Region, 1990-2030 (Estimated)
Table 2 : Recent M&A Deals in the Global Market for Women’s Health Therapeutics, 2019-2021
Table 3 : Novel Breast Cancer Drug Approvals
Table 4 : Selected New Breast Cancer Drugs in Late Stages of Clinical Development
Table 5 : Pipeline Molecules, Endometriosis
Table 6 : Pipeline Molecules, Uterine Fibroids
Table 7 : Pipeline Molecules, All Other Indications
Table 8 : Pipeline Molecules, Osteoporosis
Table 9 : Elagolix Snapshot
Table 10 : Vilaprisan Snapshot
Table 11 : Evenity Snapshot
Table 12 : Relugolix Snapshot
Table 13 : Proellex Snapshot
Table 14 : Esmya Snapshot
Table 15 : TX-004HR Snapshot
Table 16 : TX-001HR Snapshot
Table 17 : Global Market for Women’s Health Therapeutics and Technologies, by Disease Area, Through 2026
Table 18 : FDA Approved Estrogen-only Medicines
Table 19 : FDA Approved Progestin-Only Medicines
Table 20 : FDA Approved Combination, Estrogen and Progestin Medicines
Table 21 : FDA Approved Combination Estrogen and Hormone Medicines
Table 22 : Vagifem (10mcg), Patent Expiration
Table 23 : Global Market for Menopause Therapeutics, by Region, Through 2026
Table 24 : Prolia/XGEVA (Denosumab) Patent Expiration
Table 25 : Global Market for Postmenopausal Osteoporosis Therapeutics, by Region, Through 2026
Table 26 : Global Market for Endometriosis Therapeutics, by Region, Through 2026
Table 27 : Commonly Prescribed Generic Drugs for the Treatment of PCOS
Table 28 : Global Market for PCOS Therapeutics, by Region, Through 2026
Table 29 : TNM Classifications of Breast Cancers
Table 30 : Global Breast Cancer Incidence, 2016-2021
Table 31 : Global Breast Cancer Incidence and Mortality, by Region, 2018
Table 32 : Types of Hormone Therapy for Breast Cancer
Table 33 : Drugs Commonly Used to Treat Breast Cancer
Table 34 : Global Market for Breast Cancer Therapeutics, by Region, Through 2026
Table 35 : Global Market for Women’s Health Therapeutics, by Region, Through 2026
Table 36 : North American Market for Women’s Health Therapeutics, by Country, Through 2026
Table 37 : North American Market for Women’s Health Therapeutics, by Disease Area Through 2026
Table 38 : U.S. Market for Women’s Health Therapeutics, by Disease Area Through 2026
Table 39 : Canadian Market for Women’s Health Therapeutics, by Disease Area, Through 2026
Table 40 : Mexican Market for Women’s Health Therapeutics, by Disease Area, Through 2026
Table 41 : European Market for Women’s Health Therapeutics, by Country, Through 2026
Table 42 : European Market for Women’s Health Therapeutics, by Disease Area, Through 2026
Table 43 : U.K. Market for Women’s Health Therapeutics, by Disease Area, Through 2026
Table 44 : German Market for Women’s Health Therapeutics, by Disease Area, Through 2026
Table 45 : French Market for Women’s Health Therapeutics, by Disease Area, Through 2026
Table 46 : Spanish Market for Women’s Health Therapeutics, by Disease Area, Through 2026
Table 47 : Italian Market for Women’s Health Therapeutics, by Disease Area, Through 2026
Table 48 : Rest of the European Market for Women’s Health Therapeutics, by Disease Area, Through 2026
Table 49 : Asia-Pacific Market for Women’s Health Therapeutics, by Disease Area, Through 2026
Table 50 : RoW Market for Women’s Health Therapeutics, by Sub-region Through 2026
Table 51 : RoW Market for Women’s Health Therapeutics, by Disease Area, Through 2026
Table 52 : South American Market for Women’s Health Therapeutics, by Disease Area, Through 2026
Table 53 : Middle East and African Market for Women’s Health Therapeutics, by Disease Area, Through 2026
Table 54 : Blockbuster Breast Cancer Pharmaceuticals, by Company Revenue, 2018-2020
Table 55 : Major Women’s Health Therapeutics Pharmaceuticals by Company Revenue, 2020
Table 56 : Global Market Shares of Women’s Health Therapeutics, by Company Revenue, 2020
Table 57 : Patent Review, 2021
Table 58 : Novel Women’s Health Therapeutic Drug Approvals, 2021
Table 59 : Selected New Women’s Health Therapeutic Drugs in Late Stages of Clinical Development
Table 60 : Marketed Products, Postmenopausal Osteoporosis
Table 61 : AbbVie: Oncology Pharmaceutical Revenue, 2018-2020
Table 62 : AbbVie Inc.: Net Revenue, 2017-2020
Table 63 : AbbVie: Oncology Pharmaceutical Product Portfolio
Table 64 : AbbVie Inc.: Marketed Products
Table 65 : AbbVie Inc.: Key Developments, 2021
Table 66 : Allergan plc: Marketed Products
Table 67 : Allergan plc: Net Revenue, 2017-2019
Table 68 : Amgen: Oncology Pharmaceutical Product Portfolio
Table 69 : Amgen: Oncology Pharmaceutical Revenue, 2018-2020
Table 70 : Amgen: Financials, 2014-2020
Table 71 : AstraZeneca: Oncology Pharmaceutical Product Portfolio
Table 72 : AstraZeneca: Oncology Pharmaceutical Revenue, 2018-2020
Table 73 : Bayer AG: Marketed Products
Table 74 : Bayer AG: Oncology Pharmaceutical Product Portfolio
Table 75 : Bayer AG: Oncology Pharmaceutical Revenue, 2018-2020
Table 76 : Bayer AG: Net Revenue, 2018-2020
Table 77 : Bristol-Myers Squibb: Oncology Pharmaceutical Product Portfolio
Table 78 : Bristol-Myers Squibb: Oncology Pharmaceutical Revenue, 2018-2020
Table 79 : Daiichi Sankyo Co. Ltd.: Marketed Products
Table 80 : Daiichi Sankyo Co. Ltd.: Net Revenue 2018-2020
Table 81 : Eli Lilly and Co.: Marketed Osteoporosis Products
Table 82 : Eli Lilly and Co.: Net Revenue, 2018-2020
Table 83 : Eli Lilly and Co.: Oncology Pharmaceutical Product Portfolio
Table 84 : Eli Lilly and Co.: Oncology Pharmaceutical Revenue, 2018-2020
Table 85 : Roche: Oncology Pharmaceutical Product Portfolio
Table 86 : Roche: Oncology Pharmaceutical Revenue, 2018-2020
Table 87 : Gilead Sciences Inc.: Oncology Pharmaceutical Product Portfolio
Table 88 : Gilead Sciences Inc.: Oncology Pharmaceutical Revenue, 2018-2020
Table 89 : Johnson & Johnson: Oncology Pharmaceutical Product Portfolio
Table 90 : Johnson & Johnson: Oncology Pharmaceutical Revenue, 2018-2020
Table 91 : Johnson & Johnson Services Inc.: Net Revenue, 2017-2020
Table 92 : Merck & Co. Inc.: Marketed Products
Table 93 : Merck & Co. Inc.: Net Revenue, 2017-2019
Table 94 : Merck & Co. Inc.: Oncology Pharmaceutical Product Portfolio
Table 95 : Merck & Co., Inc.: Oncology Pharmaceutical Revenue, 2018-2020
Table 96 : Merck KGaA Marketed Products
Table 97 : Novartis: Oncology Pharmaceutical Product Portfolio
Table 98 : Novartis: Oncology Pharmaceutical Revenue, 2018-2020
Table 99 : Novo Nordisk: Marketed Products
Table 100 : Novo Nordisk: Net Revenue, 2017-2019
Table 101 : Pfizer Inc.: Oncology Pharmaceutical Product Portfolio
Table 102 : Pfizer Inc.: Women’s Health-Marketed Products, by Indication
Table 103 : Pfizer Inc.: Oncology Pharmaceutical Revenue, 2018-2020
Table 104 : Pfizer Inc. Net Revenue, 2017-2019
Table 105 : Sanofi: Oncology Pharmaceutical Product Portfolio
Table 106 : Sanofi: Oncology Pharmaceuticals Annual Revenue, 2018-2020
Table 107 : Takeda Pharmaceutical Co, Ltd.: Oncology Pharmaceutical Product Portfolio
Table 108 : Takeda Pharmaceutical Co. Ltd.: Oncology Pharmaceutical Revenue, 2019-2021
Table 109 : New Cancer Cases in the U.S., by Age Group, 2018
Table 110 : Trends in Per Capita Real GDP Growth, by OECD Region, 2012-2016
Table 111 : Glossary of Terms Used in Women’s Health Therapeutics
Table 112 : Acronyms Used in Women’s Health Therapeutics
List of Figures
Summary Figure A : Global Market for Women’s Health Therapeutics, by Disease Area, 2020-2026
Summary Figure B : Global Market for Women’s Health Therapeutics, by Region, 2020-2026
Figure 1 : Distribution of Global Elderly Population, by Age Group and Sex, 2020
Figure 2 : Distribution of Global Elderly Population, by Age Group and Sex, 2050
Figure 3 : Funding for Research in Women’s Health, by Disease Condition/Category, 2014-2016
Figure 4 : Funding for Research in Women’s Health, 2014-2016
Figure 5 : Distribution of Insurance Coverage in the U.S., by Type of Healthcare Provider, 2014
Figure 6 : Global Market for Women’s Health Therapeutics, 2018-2026
Figure 7 : Global Market Shares of Women’s Health Therapeutics, by Disease Area, 2020
Figure 8 : Global Market Shares of Women’s Health Therapeutics, by Disease Area, 2026
Figure 9 : Global Market for Menopause Therapeutics, 2020-2026
Figure 10 : Global Market for Menopause Therapeutics, by Region, 2020-2026
Figure 11 : Rate of Hospitalization for Osteoporosis in Australia, by Age Group, 2015-2016
Figure 12 : Global Market for Postmenopausal Osteoporosis Therapeutics, 2020-2026
Figure 13 : Global Market for Postmenopausal Osteoporosis Therapeutics, by Region, 2020-2026
Figure 14 : Global Market for Endometriosis Therapeutics, 2018-2026
Figure 15 : Global Market for Endometriosis Therapeutics, by Region, 2020-2026
Figure 16 : Global Market for PCOS Therapeutics, 2018-2026
Figure 17 : Global Market for PCOS Therapeutics, by Region, 2018-2026
Figure 18 : Global Market for Breast Cancer Therapeutics, 2018-2026
Figure 19 : Global Market for Breast Cancer Therapeutics, by Region, 2020-2026
Figure 20 : Global Market for Women’s Health Therapeutics, by Region, 20202026
Figure 21 : North American Market Shares of Women’s Health Therapeutics, by Country, 2020
Figure 22 : North American Market for Women’s Health Therapeutics, 2018-2026
Figure 23 : North American Market Shares of Women’s Health Therapeutics, by Disease Area, 2020
Figure 24 : North American Market for Women’s Health Therapeutics, by Country, 2020-2026
Figure 25 : U.S. Market for Women’s Health Therapeutics, 2018-2026
Figure 26 : Canadian Market for Women’s Health Therapeutics, 2018-2026
Figure 27 : Mexican Market for Women’s Health Therapeutics, 2018-2026
Figure 28 : European Market for Women’s Health Therapeutics, by Country, 2020-2026
Figure 29 : European Market Shares of Women’s Health Therapeutics, by Country, 2020
Figure 30 : European Market for Women’s Health Therapeutics, 2018-2026
Figure 31 : European Market Shares of Women’s Health Therapeutics, by Disease Area, 2020
Figure 32 : U.K. Market for Women’s Health Therapeutics, 2018-2026
Figure 33 : German Market for Women’s Health Therapeutics, 2018-2026
Figure 34 : French Market for Women’s Health Therapeutics, 2018-2026
Figure 35 : Spanish Market for Women’s Health Therapeutics, 2018-2026
Figure 36 : Italian Market for Women’s Health Therapeutics, 2018-2026
Figure 37 : Rest of the European Market for Women’s Health Therapeutics, 2018-2026
Figure 38 : Asia-Pacific Market for Women’s Health Therapeutics, 2018-2026
Figure 39 : Asia-Pacific Market Shares of Women’s Health Therapeutics, by Disease Area, 2020
Figure 40 : Asia-Pacific Market Shares of Women’s Health Therapeutics, by Disease Area, 2020
Figure 41 : Asia-Pacific Market for Women’s Health Therapeutics, by Disease Area, 2020-2026
Figure 42 : Chinese Market for Women’s Health Therapeutics, 2018-2026
Figure 43 : Japanese Market for Women’s Health Therapeutics, 2018-2026
Figure 44 : Indian Market for Women’s Health Therapeutics, 2018-2026
Figure 45 : South Korean Market for Women’s Health Therapeutics, 2018-2026
Figure 46 : Rest of Asia-Pacific Countries’ Market for Women’s Health Therapeutics, 2018-2026
Figure 47 : RoW Market for Women’s Health Therapeutics, by Sub-region, 2018-2026
Figure 48 : RoW Market Shares of Women’s Health Therapeutics, by Subregion, 2020
Figure 49 : RoW Market for Women’s Health Therapeutics, 2018-2026
Figure 50 : RoW Market Shares of Women’s Health Therapeutics, by Disease Area, 2020
Figure 51 : South American Market for Women’s Health Therapeutics, 2018-2026
Figure 52 : South American Market Shares of Women’s Health Therapeutics, by Disease Area, 2020
Figure 53 : Middle East and African Market for Women’s Health Therapeutics, 2018-2026
Figure 54 : Global Market Shares of Women’s Health Therapeutics, by Company, 2020
Figure 55 : AbbVie: Hematologic Oncology Annual Revenue, 2018-2020
Figure 56 : AbbVie Inc.: Revenue Share, by Country, 2020
Figure 57 : Allergan plc: Revenue Share, by Business Segment, 2017
Figure 58 : Amgen Oncology Pharmaceuticals: Annual Revenue, 2018-2020
Figure 59 : AstraZeneca’s Oncology Segment: Annual Revenue, 2018-2020
Figure 60 : Bayer AG: Oncology Pharmaceutical Annual Revenue, 2018-2020
Figure 61 : Bayer AG: Revenue Share, by Region, 2018
Figure 62 : Bayer AG: Revenue Share, by Business Segment, 2018
Figure 63 : Bristol-Myers Squibb Oncology Pharmaceuticals: Annual Revenue, 2018-2020
Figure 64 : Daiichi Sankyo Co. Ltd.: R&D Expenditure, 2014-2016
Figure 65 : Daiichi Sankyo Co. Ltd.: Revenue Share, by Business Segment, 2018
Figure 66 : Eli Lilly and Co.: Revenue Share, by Business Segment, 2018
Figure 67 : Eli Lilly and Co.: Oncology Annual Revenue, 2018-2020
Figure 68 : Roche: Oncology Annual Revenue, 2018-2020
Figure 69 : Gilead Sciences Inc.: Oncology Pharmaceutical Annual Revenue, 2018-2020
Figure 70 : Johnson & Johnson’s Oncology Segment: Annual Revenue, 2018-2020
Figure 71 : Johnson and Johnson Services Inc.: Revenue Share, by Business Segment, 2018
Figure 72 : Johnson & Johnson Services Inc.: Revenue Share, by Region, 2018
Figure 73 : Merck & Co. Inc.: Revenue Share, by Business Segment, 2018
Figure 74 : Merck & Co. Inc.: Revenue Share, by Region, 2018
Figure 75 : Merck & Co.’s Oncology Pharmaceutical: Annual Revenue, 2018-2020
Figure 76 : Novartis’s Oncology Segment: Annual Revenue, 2018-2020
Figure 77 : Novo Nordisk: Revenue Share, by Region, 2018
Figure 78 : Novo Nordisk: Revenue Share, by Business Segment, 2018
Figure 79 : Pfizer Inc.: Oncology Segment: Annual Revenue, 2018-2020
Figure 80 : Pfizer Inc.: Revenue Share, by Region, 2018
Figure 81 : Pfizer Inc.: Revenue Share, by Business Segment, 2018
Figure 82 : Sanofi: Oncology Pharmaceuticals, Annual Revenue, 2018-2020
Figure 83 : Takeda Pharmaceutical: Oncology Annual Revenue, 2019-2021
Figure 84 : Rate of New Cancer Cases in the U.S., by Age Group, 2018
Companies Mentioned
- Abbvie Inc.
- Amgen Inc.
- Asahi Kasei
- Astrazeneca plc
- Bayer AG
- Bristol-Myers Squibb
- Daiichi Sankyo Co. Ltd.
- Eisai
- Eli Lilly and Co.
- F. Hoffmann-La Roche Ltd.
- Gilead Sciences Inc.
- Johnson & Johnson Services Inc.
- Merck & Co. Inc.
- Merck Kgaa
- Novartis AG
- Novo Nordisk
- Pfizer Inc.
- Sanofi
- Takeda Pharmaceutical Co. Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 258 |
| Published | January 2022 |
| Forecast Period | 2021 - 2026 |
| Estimated Market Value ( USD | $ 54.4 Billion |
| Forecasted Market Value ( USD | $ 70.8 Billion |
| Compound Annual Growth Rate | 5.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 19 |
